A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B

Digestive and Liver Disease

Volumn 49, Issue 8, 2017, Pages 910-917

  Xu, Liang ^a,b,d   Lu, Wei ^a,c,d   Li, Ping ^b,d   Shen, Feng ^e   Mi, Yu Qiang ^b,d   Fan, Jian Gao ^e  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN SECOND PEOPLE S HOSPITAL   (China)

^c TIANJIN FIRST CENTRAL HOSPITAL   (China)

^d Tianjin Cardiovascular Diseases Institute   (China)

^e XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Assessment; Fatty liver disease; Liver biopsy; Transient elastography

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHRONIC HEPATITIS B; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; ELASTOGRAPH; EVALUATION STUDY; FATTY LIVER; FEMALE; HEPATIC STEATOSIS INDEX; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; TRANSIENT ELASTOGRAPHY; ADOLESCENT; CHINA; COMPLICATION; DIAGNOSTIC IMAGING; ELASTOGRAPHY; LIVER; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BODY MASS INDEX; CHINA; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85017516387     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2017.03.013     Document Type: Article

References (52)

1. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease. Gastroenterology 142 (2012), 1592–1609.
2. AASLD/IDSA, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
3. O'shea, R.S., Dasarathy, S., McCullough, A.J., Alcoholic liver disease. American Journal of Gastroenterology 105 (2010), 14–32.
4. Terrault, N.A., Bzowej, N.H., Chang, K., et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
5. Singh, S., Allen, A.M., Wang, Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clinical Gastroenterology and Hepatology, 13, 2015 643–54.e1-9.
6. Castera, L., Hezode, C., Roudot-Thoraval, F., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52 (2003), 288–292.
7. Lok, A.S., Everhart, J.E., Chung, R.T., et al. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clinical Gastroenterology and Hepatology 5 (2007), 245–254.
8. Dyal, H.K., Aguilar, M., Bhuket, T., et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients. Digestive Diseases and Sciences 60 (2015), 2813–2824.
9. Berzigotti, A., Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease. Journal of Hepatology 60 (2014), 910–912.
10. Grant, A., Neuberger, J., Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 45:Suppl. 4 (1999), 1–11.
11. Lassailly, G., Caiazzo, R., Buob, D., et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149 (2015), 379–388.
12. Raptis, D.A., Fischer, M.A., Graf, R., et al. MRI: the new reference standard in quantifying hepatic steatosis?. Gut 61 (2012), 117–127.
13. Wu, C., Ho, M., Jeng, Y., et al. Quantification of hepatic steatosis. Journal of Gastroenterology and Hepatology 29 (2014), 807–813.
14. Karlas, T., Petroff, D., Is magnetic resonance imaging really more accurate for classifying steatosis than controlled attenuation parameter?. Gastroenterology 151 (2016), 374–375.
15. EASL-EASD-EASO, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology 64 (2016), 1388–1402.
16. Wong, G.L., Wong, V.W., Fat and fiber: how the controlled attenuation parameter complements noninvasive assessment of liver fibrosis. Digestive Diseases and Sciences 60 (2015), 9–12.
17. Sasso, M., Miette, V., Sandrin, L., et al. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clinics and Research in Hepatology and Gastroenterology 36 (2012), 13–20.
18. Shen, F., Zheng, R.D., Lissandrin, R., et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World Journal of Gastroenterology 20 (2014), 4702–4711.
19. Ferraioli, G., Tinelli, C., Lissandrin, R., et al. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World Journal of Gastroenterology 20 (2014), 6626–6631.
20. Sasso, M., Beaugrand, M., de Ledinghen, V., et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound in Medicine and Biology 36 (2010), 1825–1835.
21. de Lédinghen, V., Vergniol, J., Foucher, J., et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver International 32 (2012), 911–918.
22. Myers, R.P., Pollett, A., Kirsch, R., et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver International 32 (2012), 902–910.
23. Carvalhana, S., Leitao, S., Alves, A.C., et al. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver International 34 (2014), e111–e117.
24. de Lédinghen, V., Vergniol, J., Capdepont, M., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. Journal of Hepatology 60 (2014), 1026–1031.
25. Yilmaz, Y., Yesil, A., Gerin, F., et al. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scandinavian Journal of Gastroenterology 49 (2014), 611–616.
26. Lee, J.H., Kim, D., Kim, H.J., et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Digestive and Liver Disease 42 (2010), 503–508.
27. Hamaguchi, M., Kojima, T., Itoh, Y., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. American Journal of Gastroenterology 102 (2007), 2708–2715.
28. Wong, G.L., Transient elastography: kill two birds with one stone?. World Journal of Hepatology 5 (2013), 264–274.
29. Sandrin, L., Tanter, M., Gennisson, J.L., et al. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control 49 (2002), 43–446.
30. Boursier, J., Zarski, J.P., de Ledinghen, V., et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57 (2013), 1182–1191.
31. Knodell, R.G., Ishak, K.G., Black, W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981), 431–435.
32. Ishak, K., Baptista, A., Bianchi, L., et al. Histological grading and staging of chronic hepatitis. Journal of Hepatology 22 (1995), 696–699.
33. Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American Journal of Gastroenterology 94 (1999), 2467–2474.
34. Wong, V.W.S., Wong, G.L.H., Chu, W.C.W., et al. Hepatitis B virus infection and fatty liver in the general population. Journal of Hepatology 3 (2012), 533–540.
35. Thomopoulos, K.C., Arvaniti, V., Tsamantas, A.C., et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. European Journal of Gastroenterology and Hepatology 18 (2006), 233–237.
36. Wang, C.C., Hsu, C.S., Liu, C.J., et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. Journal of Gastroenterology and Hepatology 23 (2008), 779–782.
37. Wang, M.M., Wang, G.S., Shen, F., et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Digestive Diseases and Sciences 59 (2014), 2571–2579.
38. Jin, X., Chen, Y.P., Yang, Y.D., et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One, 7, 2012, e34198.
39. Ates, F., Yalniz, M., Alan, S., Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World Journal of Gastroenterology 17 (2011), 4517–4522.
40. Liu, Y.L., Patman, G.L., Leathart, J.B.S., et al. Carriage of the PNPLA3 rs738409C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of Hepatology 61 (2014), 75–81.
41. Schwenzer, N.F., Springer, F., Schraml, C., et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomograpy and magnetic resonance. Journal of Hepatology 51 (2009), 433–445.
42. Palmentieri, B., de Sio, I., La Mura, V., et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Digestive and Liver Disease 38 (2006), 485–489.
43. Foster, K.J., Dewbury, K.C., Griffith, A.H., et al. The accuracy of ultrasound in the detection of fatty infiltration of the liver. The British Journal of Radiology 53 (1980), 440–442.
44. AIShaalan, R., Aljiffry, M., AI-Busafi, S., et al. Nonalcoholic fatty liver disease: noninvasive methods of diagnosing hepatic steatosis. The Saudi Journal of Gastroenterology 21 (2015), 64–70.
45. Castera, L., Non-invasive diagnosis of steatosis and fibrosis. Diabete & Metabolisme 34 (2008), 674–679.
46. Boursier, J., Cales, P., Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat. Liver International 32 (2012), 875–877.
47. Poynard, T., Patziu, V., Naveau, S., et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comparative Hepatology, 4, 2005, 10.
48. Chon, Y.E., Jung, K.S., Kim, S.U., et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver International 34 (2014), 102–109.
49. Thierry, P., Guillaume, L., Emmanuel, D., et al. Performance of biomarkers FibroTest, ActiTest SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One, 7, 2012, e30325.
50. Bedogni, G., Bellentani, S., Miglioli, L., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 6, 2006, 33.
51. Jung, K.S., Kim, B.K., Kim, S.U., et al. Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. PLoS One, 9, 2014, e98689.
52. Imajo, K., Kessoku, T., Honda, Y., et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150 (2016), 626–637.